Evidence map›Paper›PMID 34967151›Full record

ArticleCancer reports (Hoboken, N.J.)2022

Description of longitudinal tumor evolution in a case of multiply relapsed clear cell sarcoma of the kidney.

Tomoki Yaguchi, Shunsuke Kimura, Masahiro Sekiguchi, Yasuo Kubota, Masafumi Seki, Kenichi Yoshida, Yuichi Shiraishi, Keisuke Kataoka, Yoichi Fujii, Kentaro Watanabe and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Tomoki YaguchiDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-1903-6922
Shunsuke KimuraDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2158-467X
Masahiro SekiguchiDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yasuo KubotaDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-7909-5422
Masafumi SekiDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kenichi YoshidaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yuichi ShiraishiDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Keisuke KataokaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoichi FujiiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kentaro WatanabeDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitsuteru HiwatariDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Satoru MiyanoLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPKyoto University · JPHiroshima University · JP

Funding

Japan Agency for Medical Research and Development JP19ck0106468h0001Japan Agency for Medical Research and Development JP19cm0106509h9904Japan Agency for Medical Research and Development JP20cm0106501h0005Japan Society for the Promotion of Science JP17H04224Japan Society for the Promotion of Science JP18K19467Japan Society for the Promotion of Science JP19H05656Japan Society for the Promotion of Science JP20H00528Japan Society for the Promotion of Science JP26221308Princess Takamatsu Cancer Research Fund
6 · The paper itself

Abstract

backgroundClear cell sarcoma of the kidney (CCSK) is the second most common pediatric renal tumor. CASE: A 2-year-old boy was diagnosed with CCSK, which relapsed four times until he yielded to the disease at the age of 7 years. To characterize the longitudinal genetic alterations occurring in the present case, we performed targeted-capture sequencing by pediatric solid tumors panel (381 genes) for longitudinally sampled tumors, including autopsy samples of metastasis. Internal tandem duplication of BCOR (BCOR-ITD) was the only truncal mutation, confirming the previously reported role of BCOR-ITD in CCSK.

conclusionAcquisition of additional mutations along tumor relapses and detection of metastasis-specific mutations were reminiscent of the tumor progression and therapeutic resistance of this case, leading to clonal selection and a dismal fate.

Indexed as

ChildFatal OutcomeHumansKidney NeoplasmsMaleNeoplasm MetastasisNeoplasm Recurrence, LocalProto-Oncogene ProteinsRepressor ProteinsSarcoma, Clear CellBCOR protein, humanProto-Oncogene ProteinsRepressor ProteinsBCOR-ITDclear cell sarcoma of the kidneyclonal evolutionrelapse

Identifiers

PMID34967151
PMCPMC8842696
OpenAlexW4200134608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.